SCHEMBL1496925

SCHEMBL1496925

CC(C)(C)OC(=O)Nc1cscc1NC(=O)c1ccc(C(CCN2CCOCC2)NC(=O)NCCc2ccccc2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP1 P29466 1/20 0.37
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SIGMAR1 Q99720 3/20 0.36
CTSK P43235 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496988 0.96 SIGMAR1 (0.39) CD274MEN1KMT2AKDM4EALDH1A1
SCHEMBL1496874 0.95 SIGMAR1 (0.38) CD274MEN1KMT2AKDM4EALDH1A1
SCHEMBL1496924 0.93 SIGMAR1 (0.39) KDM4EALDH1A1SIGMAR1CTSKCCR2
SCHEMBL1497011 0.93 SIGMAR1 (0.41) CD274KDM4EALDH1A1GAALMNA
SCHEMBL3218374 0.91 SIGMAR1 (0.40) CD274MEN1KMT2AKDM4EALDH1A1
SCHEMBL3228228 0.90 SIGMAR1 (0.40) CD274MEN1KMT2AKDM4EALDH1A1
SCHEMBL3227868 0.90 SIGMAR1 (0.39) CD274MEN1KMT2AKDM4EALDH1A1
SCHEMBL1496947 0.89 SIGMAR1 (0.41) KMT2ASIGMAR1CTSKCCR2TACR2
SCHEMBL3224428 0.88 SIGMAR1 (0.40) KMT2AKDM4EALDH1A1SIGMAR1CTSK
SCHEMBL1497166 0.87 ALDH1A1 (0.41) MEN1KMT2AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 CD274 4096/4885MEN1 2127/4885KMT2A 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.